- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Alachua Today
By the People, for the People
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption
Company outlines mission to make peripheral nerve function restoration a standard of care at Raymond James Conference
Published on Mar. 6, 2026
Got story updates? Submit your updates here. ›
AxoGen (NASDAQ:AXGN) used its presentation at the 47th annual Raymond James Institutional Investors Conference to outline its mission to make restoration of peripheral nerve function an expected standard of care, while also providing updates on growth expectations, reimbursement progress, and the implications of its recently secured FDA Biologics License Application (BLA) for its AVANCE Nerve Graft.
Why it matters
AxoGen is seeking to expand peripheral nerve repair as a standard of care, as nerve assessment and repair are often overlooked after trauma or during other surgical procedures, leaving patients with long-term functional deficits. The company's recent FDA BLA approval for its AVANCE Nerve Graft provides validation for existing users and may help convince physicians who were 'sitting on the fence' about the product.
The details
CEO Mike Dale described peripheral nerve function as foundational to everyday motor and sensory activity, but said nerve care is often not systematically addressed after trauma or during other surgical interventions. He highlighted two primary sources of nerve injury: trauma and iatrogenic injury resulting from surgeries that transect or damage nerves. Dale said nerves do not regenerate on their own and require repair and reconstruction to restore function. AxoGen has prioritized four market development areas: extremities, breast reconstruction, oral maxillofacial/head and neck, and prostate care. The company's formal strategic plan outlook of 15% to 20% growth over the next three to five years assumes growth from the first three markets and does not include prostate. AxoGen's portfolio includes the AVANCE Nerve Graft, which Dale called the foundational product of the business and 'the first-ever approved biologic therapeutic solution' for treating nerve discontinuities, with a generalized indication for use throughout the body.
- AxoGen expects to gain full coverage for nerve repair from remaining payers by the end of its strategic planning period in 2028.
- AxoGen expects to draw conclusions on its prostate care initiative in the second half of 2026, toward the end of the third quarter and into the fourth quarter.
The players
Mike Dale
CEO of AxoGen, Inc.
Lindsey Hartley
CFO of AxoGen, Inc.
AxoGen, Inc.
A Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
